Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy
NCT ID: NCT01736059
Last Updated: 2026-01-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE1
15 participants
INTERVENTIONAL
2012-07-31
2026-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase 1 Study of Intravitreal Autologous CD34+ Stem Cell Therapy for Retinitis Pigmentosa
NCT04925687
Treatment of Central Retinal Vein Occlusion Using Stem Cells Study
NCT03981549
Treatment of Optic Neuropathies Using Autologous Bone Marrow-Derived Stem Cells
NCT02638714
Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis Pigmentosa
NCT01068561
Stem Cells Therapy in Degenerative Diseases of the Retina
NCT03772938
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Stem cell treated
CD34+ bone marrow stem cells intravitreal
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CD34+ bone marrow stem cells intravitreal
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* visual acuity 20/100 to CF
* duration of vision loss \> 3 months
* vision loss from macular degeneration, retinitis pigmentosa, retinal vein occlusion or diabetic retinopathy
* the study eye has the worse visual acuity
* no active eye or systemic disease
* no history of macular edema or retinal/choroidal neovascularization requiring treatment within 6 months
* no significant media opacity
* no coagulopathy or other hematologic abnormality
* no concurrent immunosuppressive therapy
* able to keep follow-up for 6 months
Exclusion Criteria
* other concurrent retinal or optic nerve disease affecting vision
18 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of California, Davis
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Susanna s Park, MD PhD
Role: PRINCIPAL_INVESTIGATOR
University of California Davis Eye Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California Davis
Sacramento, California, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Park SS. Cell Therapy Applications for Retinal Vascular Diseases: Diabetic Retinopathy and Retinal Vein Occlusion. Invest Ophthalmol Vis Sci. 2016 Apr 1;57(5):ORSFj1-ORSFj10. doi: 10.1167/iovs.15-17594.
Park SS, Bauer G, Abedi M, Pontow S, Panorgias A, Jonnal R, Zawadzki RJ, Werner JS, Nolta J. Intravitreal autologous bone marrow CD34+ cell therapy for ischemic and degenerative retinal disorders: preliminary phase 1 clinical trial findings. Invest Ophthalmol Vis Sci. 2014 Dec 9;56(1):81-9. doi: 10.1167/iovs.14-15415.
Related Links
Access external resources that provide additional context or updates about the study.
Learn more or sign up for the study here!
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BMSCRetPilot
Identifier Type: OTHER
Identifier Source: secondary_id
906595
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.